FDA Panel's 'Grifters' Accusation: The Backlash Against RFK Jr.'s Peptide Push

On August 24, 2026, the Genetic Literacy Project published a viewpoint that called the FDA's newly reconstituted Pharmacy Compounding Advisory Committee a panel of "physician grifters," accusing Health and Human Services Secretary Robert F. Kennedy Jr. of stacking the committee to legitimize what the authors termed a "cure-all" peptides craze. The piece landed five weeks after the panel's July 23-24 vote at the agency's White Oak campus in Silver Spring, Maryland, and it sharpened a conflict that had been building inside the FDA since spring: career scientists who found no adequate human safety data for the compounds in question versus political appointees who voted to advance them anyway.

The vote itself was narrow. Across a series of roll calls, eight panel members voted in favor of placing BPC-157, KPV, TB-500, MOTS-c, Semax, and epitalon on the Section 503A Bulks List, with six voting against and one abstaining, as reported by the American Journal of Managed Care. A seventh compound, emideltide, was rejected. FDA staff scientists had recommended against adding all seven peptides, citing what they described as an effective absence of human clinical data. The panel's majority overrode that guidance.

The recommendation carries no legal force on its own. Placement on the 503A Bulks List would permit state-licensed compounding pharmacies to prepare the substances for individual patients holding prescriptions, but only after the FDA completes formal notice-and-comment rulemaking. None of the six peptides holds an FDA-approved indication, standardized dosing, or validated manufacturing specification. Whether the agency will adopt the panel's advice, and on what timeline, remains an open question as of this writing. For readers tracking the distinction between compounding access and drug approval, our guide on fda approved peptides details the regulatory gap.

The Vote Against Scientific Advice

FDA career scientists presented their assessments over two days of testimony and written briefs. Their position was unanimous: the evidence did not support adding any of the seven peptides under review. For BPC-157, the agency noted that no published studies examined its use in humans. TB-500, which the FDA described as initially developed as a veterinary performance drug for horse and greyhound racing, similarly lacked human trial data. Epitalon raised specific concerns about immunogenicity, manufacturing impurities, and potential carcinogenicity linked to its telomere-extending mechanism.

The panel's majority did not adopt those findings. In the first vote on BPC-157, six members with commercial ties to peptide sales joined a compounding pharmacist and a pharmacy business executive to produce the 8-6 margin, according to reporting by the Associated Press. Panel members with academic backgrounds, rather than peptide-commerce backgrounds, voted predominantly against the recommendations.

The Genetic Literacy Project's August 24 viewpoint seized on that composition. Citing a New York Times investigation, the authors reported that six of the eight Kennedy-appointed members had sold peptides or held affiliations with clinics marketing them. The piece singled out Dr. Gabriel Alizaidy, identified as scientific director at Maximus, a telehealth company selling growth hormone peptides at roughly $200 per month. Maximus had previously received an FDA warning letter over claims about compounded weight-loss medications. The authors argued that treating patient access as the controlling principle "sidelines the scientific criteria the agency is required to weigh" under Section 503A.

Conflicts of Interest and the Kennedy Connection

Kennedy entered his role at HHS promising to end what he called the FDA's "aggressive suppression" of peptides. He has described himself as a "big fan" of the compounds and argued that the agency's 2023 restrictions pushed consumers toward unregulated grey market peptides, a safety concern he said compounding oversight could address. His office handpicked the new panelists over the objections of FDA staff, who raised concerns about potential conflicts of interest before the July meeting, according to reporting cited by Protect Our Care. Those concerns, an FDA insider told STAT, were ignored.

The Genetic Literacy Project framed the panel's work as an extension of Kennedy's personal wellness preferences rather than a scientific review. The viewpoint also noted that the broader peptide marketplace had already attracted litigation: on August 12, Eli Lilly filed suit against six U.S. sellers it accused of illegally marketing retatrutide, an experimental weight-loss peptide the FDA says cannot lawfully be compounded or sold to consumers. That enforcement action show the tension between the agency's traditional gatekeeping role and the political pressure to widen access.

The committee's recommendations are advisory. The FDA retains authority to accept, modify, or reject them. Former FDA official Ilisa Bernstein told Politico that the system "was not set up for the mass compounding that's going to be coming" if the recommendations are adopted. Consumer advocates and brand-name pharmaceutical companies have argued that broad compounding access would undercut the financial incentives for companies to pursue the multi-year, multi-hundred-million-dollar clinical trial pathway that produces are peptides legal answers through formal approval.

What Happens Next

The FDA has not announced a date for proposed rulemaking on the six peptides. Until a final rule appears in the Federal Register, compounding pharmacies lack legal authority to prepare BPC-157, TB-500, KPV, MOTS-c, Semax, or epitalon for patient prescriptions. Enforcement discretion in the interim period remains a variable that neither the agency nor HHS has publicly addressed.

The Genetic Literacy Project's "grifters" framing is an editorial characterization, not a finding by any oversight body. No federal inspector general investigation or congressional subpoena targeting the panel's conflicts has been confirmed as of August 25. The New York Times reporting on which the viewpoint relies has not been independently verified by this newsroom. What is documented in agency records is the vote count, the staff scientists' written objections, and the panel's roster. Whether the FDA Commissioner's office will treat the 8-6 recommendation as a basis for rulemaking, or set it aside pending additional safety data, is the decision now sitting on the agency's desk.